/

TLT.V

THERALASE TECHNOLOGIES INC.Closed

0.1900+0.01 +5.56%CAD

TSXV · as of Oct 14, 15:59 ET

Open

0.1850

Prev close

0.1800

Day range

0.18000.1900

52-week range

0.15000.4100

Volume

68.50K0.29×

Mkt cap

58.99M

P/E ttm

—

Fwd P/E

-19.00

EPS ttm

-0.0100

Div yield

0.00%

Earnings

—

From 52w high

−53.66%

Price Chart

Yahoo Finance · delayed

TLT.VOct 14, 2026O 0.1850H 0.1900L 0.1800C 0.1900+0.0100 (+5.56%)Vol 68.50K

SMA 500.1926
SMA 2000.2479

1Y change −9.52% since Oct 10, 2025 close539 bars loadedTimes in America/TorontoDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

TLT.V THERALASE TECHNOLOGIES INC. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +5.56%
1 month: +5.56%
3 months: −26.92%
6 months: −34.48%
Year to date: +11.76%
1 year: −5.00%

Valuation & ownership

Market cap: 58.99M
Enterprise value: 53.88M
P/E (ttm): —
Forward P/E: -19.00
PEG ratio: —
Price / book: 8.26
Price / sales (ttm): 73.51
EV / EBITDA: -14.76
EPS (ttm): -0.0100
EPS (forward): -0.0100
Beta (5y monthly): 0.41
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 310.48M
Float: 291.33M
Short % of float: —
Short ratio (days): 1.53
Held by insiders: 8.45%
Held by institutions: 0.00%
Avg volume (3m): 236.08K
50-day average: 0.1926
200-day average: 0.2479
52-week change: −5.00%
S&P 500 52-week: +15.71%

Technicals (daily)

RSI (14): 54.5
vs 50-day SMA: −1.35%
vs 200-day SMA: −23.36%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 3.88%
Realised vol (20d, ann.): 43.8%
From 52-week high: −53.66%
From 52-week low: +26.67%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

0.7000

+268.42% implied

Low 0.7000Median 0.7000High 0.7000

Recommendation trend

Now1 / 0 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →trailing twelve months

DES

About THERALASE TECHNOLOGIES INC.

Yahoo Finance profile

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma. The company also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain. Theralase Technologies Inc. is based in Toronto, Canada.

Sector: Healthcare
Industry: Medical Devices
Headquarters: Toronto, ON, Canada
Website: theralase.com
Officers: Mr. Roger John Dumoulin-White B.Sc., P.Eng. President, CEO & Chairman
Ms. Kristina Hachey CPA CFO & Director
Dr. Arkady Mandel DSc., M.D., Ph.D. Chief Scientific Officer & Director
Mr. David M. Groves B.A President of World Trade Division

SEAS

Seasonality · TLT.V

2008–2026 · monthly returns

Strongest month Dec +14.52%Weakest month Aug −7.06%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	47.1	16.0	-3.4	14.3	-28.1	13.0	11.5	-37.9	0.0	5.6			+11.8%
2025	3.7	-7.1	-26.9	-5.3	11.1	0.0	5.0	0.0	-9.5	10.5	-23.8	6.3	−37.0%
2024	-11.1	37.5	-22.7	-5.9	-12.5	50.0	-4.8	-10.0	-5.6	47.1	-12.0	22.7	+50.0%
2023	9.4	8.6	-28.9	-7.4	-4.0	12.5	3.7	-17.9	0.0	-13.0	-5.0	-5.3	−43.7%
2022	-2.6	16.2	7.0	-39.1	32.1	-18.9	10.0	-15.2	-3.6	-3.7	11.5	10.3	−15.8%
2021	21.1	21.7	-10.7	-8.0	8.7	4.0	-3.8	-4.0	-16.7	0.0	30.0	46.2	+100.0%
2020	-17.6	-7.1	-26.9	10.5	19.0	-8.0	-26.1	11.8	-26.3	-7.1	46.2	0.0	−44.1%
2019	15.6	35.1	-4.0	2.1	-4.1	2.1	-35.4	-25.8	4.3	-8.3	13.6	36.0	+6.3%
2018	-12.0	-9.1	15.0	-4.3	72.7	0.0	2.6	-10.3	-14.3	0.0	16.7	-8.6	+28.0%
2017	26.9	-15.2	17.9	45.5	-27.1	11.4	25.6	-6.1	4.3	-6.3	-42.2	-3.8	−3.8%
2016	-4.7	-4.9	-12.8	2.9	5.7	13.5	2.4	-7.0	-2.5	0.0	-30.8	-3.7	−39.5%
2015	-21.1	-11.1	-7.5	-10.8	6.1	-11.4	0.0	-12.9	7.4	0.0	10.3	34.4	−24.6%
2014	15.9	-33.3	11.8	-28.9	25.9	11.8	-2.6	-5.4	-17.1	13.8	3.0	67.6	+29.5%
2013	26.3	20.8	-6.9	-11.1	-8.3	-9.1	0.0	15.0	-4.3	-4.5	71.4	22.2	+131.6%
2012	5.7	8.1	-25.0	-20.0	-4.2	4.3	-16.7	-10.0	11.1	15.0	-26.1	11.8	−45.7%
2011	-15.5	3.3	-17.7	13.7	-13.8	-6.0	12.8	-18.9	-20.9	29.4	13.6	-30.0	−50.7%
2010	88.1	2.5	-22.2	3.2	12.3	-9.6	4.5	-24.6	30.8	4.4	2.8	-2.7	+69.0%
2009	6.7	-37.5	400.0	-42.0	-3.4	-3.6	22.2	6.1	20.0	-16.7	31.4	-8.7	+180.0%
2008			0.0	3.6	-33.3	-44.7	19.0	8.0	11.1	-70.0	0.0	66.7	−72.7%

TLT.V

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

TLT.V

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About THERALASE TECHNOLOGIES INC.

Seasonality · TLT.V

Insider Activity · TLT.V

Congress Trades · TLT.V

Investors Holding TLT.V

Investors Holding TLT.V

Congress Trades · TLT.V

Insider Activity · TLT.V

Seasonality · TLT.V

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About THERALASE TECHNOLOGIES INC.

Earnings & Dividends

News